Arrakis touts paper on RNA-targeted small molecules

By The Science Advisory Board staff writers

August 31, 2020 -- Arrakis Therapeutics is touting the publication of a new paper that demonstrates the capabilities of its proprietary Photoaffinity Evaluation of RNA Ligation-sequencing (PEARL-seq) technology for the systemic identification of binding sites in RNA molecules as a method to facilitate the discovery of RNA-targeted small molecule medicines. The research was published in the American Chemical Society's ACS Chemical Biology.

The company's PEARL-seq utilizes photoaffinity labeling of RNA in combination with next-generation sequencing and a dedicated bioinformatic analysis pipeline. The data shows that the PEARL-seq platform was able to identify ligand binding sites within a model aptamer RNA and identify potential off-target binding interactions.

The platform -- in combination with conventional RNA structure probing methods -- can be used to generate and refine 2D and 3D structures of RNA-small molecule complexes to facilitate the rational design of RNA-targeted small molecule therapeutics, according to the company.

ESMO recommends use of NGS for advanced cancers
The European Society for Medical Oncology (ESMO) released its first recommendations for the use of next-generation sequencing (NGS) for patients with...
Bio-Techne, Leica launch RNA probes for COVID-19 research
Bio-Techne and Leica Biosystems have announced the automation of RNAscope COVID-19 probes on Bond Rx, Leica's staining platform, for research use only....

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter